智通财经APP获悉，兆科眼科-B(06622)再涨超7%，截至发稿，涨6.48%，报4.27港元，成交额1087.63万港元。
消息面上，兆科眼科宣布，公司已与印尼领先制药公司PT Ferron Par Pharmaceuticals，就公司之核心产品：用于减缓儿童和青少年近视进展的硫酸阿托品滴眼液(NVK002)，签订了一份针对印尼市场的分销和供应协议。
根据协议条款，兆科眼科授予PT Ferron在印度尼西亚进口、推广、分销、营销和销售该产品的独家权利。兆科眼科将获得一笔预付款项，并可根据若干成就获得额外的里程碑付款。此外，今年稍早时候，兆科眼科硫酸阿托品滴眼液0.01%剂量之简易新药申请，以及0.02%剂量之新药申请，已先后获得中国国家药品监督管理局受理，目前正在审批过程中。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.